IP Library Patent Application 10585961
Patent Application
App. No. 10/585,961

Use Of Ribose for Recovery From Anaesthesia

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/585,961
Abstract

D-Ribose is administered before and after general anaesthesia to reduce the time to recover from the effects of general anaesthesia. Preferably, pyrogen-free D-Ribose is administered intravenously during general anaesthesia and the interval post-anaesthesia before oral administration can be resumed. D-Glucose may be co-administered to reduce the effect of hypoglycemia that may be seen with D-Ribose administration.

Claims (11)

1 . A method of reducing recovery time of a mammal undergoing general anaesthesia comprising the administration of an effective amount of D-Ribose to said mammal.

2 . The method of claim 1 wherein the effective amount of D-Ribose is administered orally before and after general anaesthesia.

3 . The method of claim 2 wherein the effective amount of D-Ribose is from 2 to 10 grams and is administered two to four times daily.

4 . The method of claim I wherein an effective amount of pyrogen-free D-Ribose is administered intravenously during and after general anaesthesia.

5 . The method of claim 4 wherein the effective amount of D-Ribose is 20-300 mg/kg/hour.

6 . A method of reducing recovery time of a mammal undergoing general anaesthesia wherein an effective amount of D-Ribose is administered orally to the mammal when the mammal is able to ingest the D-Ribose and an effective amount of pyrogen-free D-Ribose is administered intravenously to the mammal when the mammal is unconscious or otherwise unable to ingest the D-Ribose.

7 . The method of claim 6 wherein the effective amount of D-Ribose to be administered orally is 2 to 10 gm and is administered two to four times daily and the effective amount of pyrogen-free D-Ribose to be administered intravenously is 20-300 mg/kg/hour.

8 . A method for enhancing recovery from sepsis comprising of the administration of D-Ribose to the mammal suffering from sepsis.

9 . A composition suitable for intravenous administration comprising substantially pure, pyrogen-free D-Ribose.

10 . The composition of claim 9 further comprising D-Glucose.

11 . The composition of claim 10 comprising 5% to 10% pyrogen-free D-Ribose and 5% to 10% D-Glucose.

Assignments (1)
SECURITY INTEREST Recorded Oct 13, 2015
From: RIBOCOR, INC.
To: HAYDEN JR, H.B. "BUD"
Reel/Frame 036782/0429 →